中国药物经济学2016，Vol.11Issue(7)：50-52,3.DOI:10.12010/j.issn.1673-5846.2016.07.015
巴曲酶治疗急性缺血性脑卒中患者的临床疗效
The clinical efficacy of Batroxobin in Treatment of Acute Ischemic Stroke Patients
卢冲 1臧召霞 1朴钟源 1魏亚芬1
作者信息
- 1. 黑龙江省医院神经内一科，黑龙江哈尔滨 150036
- 折叠
摘要
Abstract
Objective To evaluate the clinical efficacy of batroxobin acute ischemic stroke (CIS) patients.Methods January 2014 to June 2015 during the CIS Heilongjiang Provincial Hospital admitted 64 patients as research subjects wil be divided into study group and the control group,which uses random number table,32 cases in each.The control group of patients with conventional treatment,the study group patients Batroxobin,compared two groups of patients with the therapeutic effect and safety.Results Study group of patients with total effective rate was significantly higher,the difference was statisticaly significant(P<0.05);two groups of patients before treatment with MRS NIHSS score difference was not statisticaly significant(P>0.05),treatment after 24 h and 7 d,the MRS study patients with NIHSS scores were significantly lower than the control group,the differences were statisticaly significant(P<0.05); and the post-treatment of plasma fibrinogen(FIB) were significantly lower in the control group,the differences were statisticaly significant(P<0.05).During the two groups of patients were not to see blood,urine,feces routine examination, liver and kidney function tests abnormal bleeding reactions did not occur,or no complaints of adverse reactions were observed.Conclusion Batroxobin CIS can improve the clinical efficacy,it is possible to quickly and effectively improve neurological function in patients,and fewer adverse reactions,without increasing the risk of bleeding, medication safety and reliability.关键词
巴曲酶/急性缺血性脑卒中/临床疗效Key words
Batroxobin/Acute ischemic stroke/Clinical efficacy分类
医药卫生引用本文复制引用
卢冲,臧召霞,朴钟源,魏亚芬..巴曲酶治疗急性缺血性脑卒中患者的临床疗效[J].中国药物经济学,2016,11(7):50-52,3.
